Oncoinvent to present preclinical efficacy data in a poster session at the 20th Biennial Meeting of the European Society of Gynaecological Oncology (ESGO 2017)

The poster ‘Preclinical Evaluation of a Novel Alpha-Particle Emitting Therapeutic Agent for Intraperitoneal Therapy of Peritoneal Metastases’ by Oncoinvent scientists Tina B. Bønsdorff, Sara Westrøm, Øyvind S. Bruland and Roy H. Larsen will be presented at the congress.

Organiser: ESGO
Venue:

Austria Center Vienna, Bruno Kreisky Platz 1, Vienna, 1210 Austria


Date: 4 November 2017
Program: Program

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

Largest shareholders

IR Contact

+47 22 18 33 05

Oncoinvent AS Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.

close